Pensionfund Sabic Takes $1.83 Million Position in Eli Lilly and Company $LLY

Pensionfund Sabic purchased a new position in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 1,700 shares of the company’s stock, valued at approximately $1,827,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after buying an additional 551,659 shares during the last quarter. State Street Corp grew its stake in shares of Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after acquiring an additional 219,590 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Eli Lilly and Company by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after purchasing an additional 574,229 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $8,827,714,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $898.68 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a 50-day moving average of $1,010.46 and a 200 day moving average of $960.96. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market capitalization of $849.09 billion, a price-to-earnings ratio of 39.16, a PEG ratio of 1.06 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on LLY. TD Cowen increased their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Zacks Research cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Finally, Berenberg Bank raised their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,221.44.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 earnings and revenue momentum — Coverage highlights Eli Lilly’s strong Q4 results and robust GLP‑1 sales that are driving top‑line and margin strength, supporting the company’s growth story. Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
• Positive Sentiment: Bullish long‑term thesis on GLP‑1 leadership — Retail/bullish analysis argues that Lilly’s leadership in obesity/GLP‑1 drugs makes it a durable growth compounder, reinforcing investor enthusiasm. Could Buying Eli Lilly Today Set You Up for Life?
• Positive Sentiment: Analyst model tweak — Erste Group slightly raised FY‑2026 EPS expectations for LLY (minor lift to forecasts), which supports consensus that Lilly’s earnings power is rising. MarketBeat: Eli Lilly analyst note
• Neutral Sentiment: Media/celebrity endorsement and market performance — Jim Cramer and other outlets are naming Lilly among top healthcare picks, and recent trading showed short‑term outperformance, which can attract flows but also create volatility. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Industry comparisons and valuation debate — Analyst pieces compare LLY with peers (Novo Nordisk, ABBV), highlighting strong growth but also elevated multiples — important context for investors weighing upside vs. valuation risk. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Neutral Sentiment: Investor letters and fund commentary reiterate GLP‑1 as the growth engine, but also note concentration risk (revenue tied to a few franchises). Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Negative Sentiment: Policy/reputation risk around GLP‑1s — Coverage raising the “societal obligation” and broader public debate about GLP‑1s can translate into regulatory scrutiny or reimbursement pressure, a potential near‑term headwind for sentiment. Eli Lilly and the ‘societal obligation’ of GLP-1s

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.